Poland· PL-100127269
Lumigan
A bimatoprost product containing bimatoprostum, registered in Poland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 19 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Bimatoprost is registered in 19 of 19 countries.
Countries holding a registration under ATC S01EE03 (bimatoprost), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 11 of them publish a price we can compare per daily dose
Bimatoprost · ATC S01EE03
19 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Bimatoprostum
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Poland (PL)
- ATC code
- S01EE03
- ATC class
- Bimatoprost
- Defined daily dose
- 0.1 ml, AT
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
1 priced- gtin059099900084691 but.po 3 mlPLN 37.99
- gtin05909991026295
- gtin05909990008476
- gtin05909991026288
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
89 interactions on record for bimatoprost.
Graded by severity as the source publishes them — 89 info. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bimatoprost · interactions on record
89 records
Same medicine, other countries
Bimatoprost in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesbimatoprostAlembic Pharmaceuticals Limited
- CzechiaBIMATOPROST FARMAPROJECTSFarmaprojects S.A.U., Barcelona
- NetherlandsBIMAGAN 0,3 mg/ml oogdruppels, oplossingS.C. Rompharm Company S.R.L.
- FinlandBimatoprost AccordAccord Healthcare B.V.
- SwedenBimatoprost Brown & Burk 0,3 mg/ml Ögondroppar, lösning i endosbehållareBrown & Burk IR Limited
- BelgiumBimatoprost EG 0.3 mg/mlEG
- FranceAMIRIOX 0,3 mg/mL, collyre en solutionSIFI (ITALIE)
- IrelandEyreida 0.3 mg/ml eye drops, solutionAspire Pharma (Malta) Limited
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Bima-Vision Sine, Bimato-Vision
- Belgium · Bimatoprost Eg, Bimatoprost Eg (Eurogenerics)
- Bulgaria · Бимаган, Биматопрост Абр
- Cyprus · Bimatoprost Pharmathen, Birmost
- Czechia · Bimatoprost Farmaprojects, Bimatoprost Olikla
- Germany · Amiriox, Bimato-Vision
- Denmark · Bimatoprost "hexal", Bimatoprost "stada"
- Estonia · Elymbus
- Spain · Amiriox, Bamixol
- Finland · Bimatoprost, Bimatoprost Sandoz
- France · Amiriox, Bimatoprost
- United Kingdom (Northern Ireland) · Amiriox, Bimatoprost Alissa Healthcare Research
- Greece · Birmost, Dacrysan
- Croatia · Elymbus
- Ireland · Elymbus, Eyreida
- Iceland · Bimatoprost, Elymbus
- Italy · Amiriox, Bialviz
- Liechtenstein · Lumigan
- Lithuania · Bimican, Bimifree
- Luxembourg · Bimatoprost Eg, Bimatoprost Eg (Eurogenerics) Nv
- Latvia · Bimican, Bimifre
- Netherlands · Bimagan, Bimato-Vision
- Norway · Bimaprez, Bimatoprost Hexal
- Portugal · Amiriox, Bimatoprost Stulln
- Romania · Amiriox, Bimagan
- Sweden · Bimaprez, Bimatoprost
- Slovenia · Elymbus
- Slovakia · Bimatoprost Olikla, Elymbus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dbe95d59-e67c-476c-b430-99f46330c0ea GET /v1/drugs/dbe95d59-e67c-476c-b430-99f46330c0ea?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Krople do oczu, roztwór",
"source": "urpl",
"strength": "0,3 mg/ml",
"packaging": "05909991026295 ¦ Rp ¦ EU/1/02/205/006 ¦ 12595\n30 poj. 0,4 ml\n05909990008469 ¦ Rp ¦ EU/1/02/205/001 ¦ 24244\n1 butelka 3 ml\n05909990008476 ¦ Rp ¦ EU/1/02/205/002 ¦ 24245\n3 butelki 3 ml\n05909991026288 ¦ Rp ¦ EU/1/02/205/005 ¦ 80661\n5 poj. 0,4 ml\nRp ¦ EU/1/02/205/007 ¦ 122617\n90 poj. 0,4 ml",
"substance": "Bimatoprostum 0.3 mg/ml",
"common_name": "Bimatoprostum",
"pl_product_id": "100127269",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about bimatoprost.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.